思路迪医药
3D Medicines

3D Medicines Inc.
思路迪医药股份有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1244)

DISCLOSEABLE TRANSACTION

The Board hereby announces the details of the extension of a short-term note (the "**Note**") entered into by the Group, which constitutes a discloseable transaction under Chapter 14 of the Listing Rules.Unless otherwise stated, all the capitalised terms used herein shall have the same meaning as those adopted in the Annual Report.

1. BACKGROUND

On August 14, 2023, 3D Medicines (Hong Kong) Co., Limited ("**3D Medicines HK**"), a wholly-owned subsidiary of the Company, entered into a short-term note agreement (the "**Initial Agreement**") with Mega Link International Limited ("**Mega Link**"), an independent third party, with a principal amount of HK$50,000,000. The coupon rate is 6% per annum for the period from August 14, 2023 to August 14, 2025, and 7.5% per annum for the period from August 15, 2025 to August 14, 2026.

The Note was extended for the first time on August 15, 2024, and for the second time on August 15, 2025, with the principal amount remaining unchanged except for the interest rate adjusted in accordance with the agreement.

In order to optimize the Group's capital allocation and continue to earn stable investment returns through prudent financial management, 3D Medicines HK and Mega Link entered into a Note Instrument Supplementary Agreement (the "**Extension Agreement**") in 2026, to extend the maturity date of the Note.

2. DETAILS OF THE EXTENSION AGREEMENT

Item	Details
Parties to the Agreement	Subscriber (Lender): 3D Medicines (Hong Kong) Co., Limited Issuer (Borrower): Mega Link International Limited
Date of the Extension Agreement	August 15, 2026
Principal Amount	HK$50,000,000
Coupon Rate	9% per annum
Extended Maturity Date	August 14, 2028
Early Redemption Arrangement	3D Medicines HK has the right to serve a 15-day prior written notice to Mega Link to demand immediate redemption of the Note, with repayment of the principal amount together with all accrued interest and other due amounts
Interest Payment Terms	The outstanding accrued interest for the period from August 14, 2023 to August 14, 2026 shall be settled separately in accordance with the terms agreed by the parties. Interest accrued from August 15, 2026 shall be payable to the Subscriber on the Maturity Date or on the date of early redemption request
Event of Default Arrangement	In the event of any continuing default by Mega Link (including failure to pay due amounts, material breach of obligations, material adverse change in solvency, winding-up or bankruptcy proceedings etc.), 3D Medicines HK may declare all indebtedness under the Agreement immediately due and payable, and require Mega Link to redeem the Note immediately
Governing Law and Dispute Resolution	This Agreement shall be governed by and construed in accordance with the laws of Hong Kong. Any dispute arising out of or in connection with this Agreement shall be finally resolved by arbitration administered by the Hong Kong International Arbitration Centre ("**HKIAC**") in accordance with the HKIAC Administered Arbitration Rules in force when the Notice of Arbitration is submitted. The seat of arbitration shall be Hong Kong, the number of arbitrators shall be one, and the arbitration proceedings shall be conducted in English. The arbitral award shall be final and binding on both parties

3. LISTING RULES IMPLICATIONS

As the highest of the applicable percentage ratios in respect of the extension of the Note under the Extension Agreement is higher than 5% but less than 25%, the extension of the Note under the Extension Agreement constitutes a discloseable transaction for the Company under Chapter 14 of the Listing Rules and is subject to the notification and announcement requirements under the Listing Rules.

4. REASONS FOR AND BENEFITS OF THE TRANSACTION

By extending the Note, the Group can continue to obtain stable interest income, improve the efficiency of capital utilization, and the funds generated from the transaction will be used to supplement the Group's research and development investment and daily operating capital, which is beneficial to the overall interests of the Company and its shareholders as a whole.

5. INFORMATION ON THE COUNTERPARTY AND THE GROUP

Mega Link International Limited is an independent third party to the Company, its connected persons (as defined under the Listing Rules) and any of its subsidiaries. Based on the information obtained by the Company, Mega Link is in sound financial condition with a normal credit record, and has the ability to perform its obligations under the note supplementary agreement. Mega Link is a company incorporated under the laws of the British Virgin Islands.

The Company is an investment holding company and its subsidiaries are principally engaged in the research and development of oncology therapies for cancer patients, especially those who require long-term care.

6. DIRECTORS' CONFIRMATION

The directors of the Company confirm that the terms of the Extension Agreement are fair and reasonable, the transaction is entered into in the ordinary and usual course of business, and the transaction is in the overall interests of the Company and its shareholders as a whole.

7. GENERAL

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company. For further information, please refer to the Company's subsequent announcements.

8. DEFINITIONS

In this announcement, the following expressions shall have the following meanings:

The Company	3D Medicines Inc., a company incorporated in the Cayman Islands with limited liability, whose shares are listed on the Stock Exchange (Stock Code: 1244)
The Group	The Company and its subsidiaries
The Board	The board of directors of the Company

The Stock Exchange	The Stock Exchange of Hong Kong Limited
Listing Rules	The Rules Governing the Listing of Securities on the Stock Exchange
3D Medicines HK	3D Medicines (Hong Kong) Co., Ltd., a wholly-owned subsidiary of the Company
Mega Link	Mega Link International Limited, the borrower of the Note
Short-term Note/The Note	The debt instrument under the short-term note agreement signed between 3D Medicines HK and Mega Link on August 14, 2023, with a principal amount of HK$50,000,000, which was subsequently extended by the First Extension on August 15, 2024, and further extended on August 15, 2025, the coupon rate is 6% per annum for the period from August 14, 2023 to August 14, 2025, and 7.5% per annum for the period from August 15, 2025 to August 14, 2026
Initial Agreement	The "Note Instrument" signed between 3D Medicines HK and Mega Link International Limited on August 14, 2023
First Extension	The first extension to the Initial Agreement signed between 3D Medicines HK and Mega Link International Limited on August 15, 2024
Extension Agreement	The "NOTE INSTRUMENT Supplementary Agreement" signed between 3D Medicines HK and Mega Link International Limited on August 15, 2026, aiming to extend the maturity date of the Note
RMB/HK$	Renminbi, the legal tender of the People's Republic of China/ Hong Kong Dollar, the legal tender of Hong Kong
%	Percentage

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong, September 17, 2026

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Ms. ZHANG Wenhua, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.